Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
R. E. Nappi, L. Tiranini, E. Martini, D. Bosoni, C. Cassani & L. Cucinella. (2023) Different local estrogen therapies for a tailored approach to GSM. Climacteric 26:4, pages 361-366.
Read now
Read now
Marcos J. Cuerva, Silvia P. González, Jesús Lazaro-Carrasco De La Fuente, Francisco J. Lopez & Concepción Nieto. (2022) Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study. Journal of Obstetrics and Gynaecology 42:7, pages 3397-3399.
Read now
Read now
Andrea R. Genazzani, Patrizia Monteleone, Andrea Giannini & Tommaso Simoncini. (2021) Pharmacotherapeutic options for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy 22:13, pages 1773-1791.
Read now
Read now
Natalícia de Jesus Antunes, Raimundo Vieira de Oliveira Filho, Jaime de Oliveira Ilha, Ronilson A. Moreno, André Felipe Nahoum, Ralph-Steven Wedemeyer, André Warnke & Gilberto De Nucci. (2021) Single-dose pharmacokinetics and pharmacodynamics assessment of oestriol and trimegestone containing vaginal rings in healthy women with childbearing potential. The European Journal of Contraception & Reproductive Health Care 26:3, pages 184-194.
Read now
Read now
Federica Palma, Anjeza Xholli & Angelo Cagnacci. (2017) Management of vaginal atrophy: a real mess. Results from the AGATA study. Gynecological Endocrinology 33:9, pages 702-707.
Read now
Read now
G. P. Siliquini, V. Tuninetti, V. E. Bounous, F. Bert & N. Biglia. (2017) Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. Climacteric 20:4, pages 379-384.
Read now
Read now
M. L’Hermite. (2017) Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric 20:4, pages 331-338.
Read now
Read now
Articles from other publishers (13)
Abbie Laing & Tim Hillard. (2023) Oestrogen-based therapies for menopausal symptoms. Best Practice & Research Clinical Endocrinology & Metabolism, pages 101789.
Crossref
Crossref
Rossella E. Nappi, Laura Cucinella, Ellis Martini & Chiara Cassani. (2021) The role of hormone therapy in urogenital health after menopause. Best Practice & Research Clinical Endocrinology & Metabolism 35:6, pages 101595.
Crossref
Crossref
Nèvine West, Richard Day, Garry Graham, Michael Wright, Christopher White, Gordana Popovic & Kate Hilda Moore. (2020) Serum concentrations of estriol vary widely after application of vaginal oestriol cream. British Journal of Clinical Pharmacology 87:5, pages 2354-2360.
Crossref
Crossref
Pedro Sánchez-Rovira, Angelica Lindén Hirschberg, Miguel Gil-Gil, Begoña Bermejo-De Las Heras & Concepción Nieto-Magro. (2020) A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. The Oncologist 25:12, pages e1846-e1854.
Crossref
Crossref
Zhenxing Si, Shifeng Zhou, Zilong Shen & Feiyu Luan. (2020) High-Throughput Metabolomics Discovers Metabolic Biomarkers and Pathways to Evaluating the Efficacy and Exploring Potential Mechanisms of Osthole Against Osteoporosis Based on UPLC/Q-TOF-MS Coupled With Multivariate Data Analysis. Frontiers in Pharmacology 11.
Crossref
Crossref
Angelica Lindén Hirschberg, Pedro Sánchez-Rovira, Jesús Presa-Lorite, Miriam Campos-Delgado, Miguel Gil-Gil, Elisabet Lidbrink, Javier Suárez-AlmarzaConcepción Nieto-Magro. (2020) Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause 27:5, pages 526-534.
Crossref
Crossref
Sônia M.R.R. Lima & Juliana V. Honorato. (2019) Critical analysis of methods for assessing genitourinary syndrome of menopause used in clinical trials. Menopause 26:12, pages 1436-1442.
Crossref
Crossref
Angelo Cagnacci, Mario Gallo, Marco Gambacciani & Stefano Lello. (2019) Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE). Minerva Ginecologica 71:5.
Crossref
Crossref
Raimundo Vieira de Oliveira Filho, Natalícia de Jesus Antunes, Jaime de Oliveira Ilha, Ronilson Agnaldo Moreno, Ralph‐Steven Wedemeyer, André Warnke & Gilberto De Nucci. (2018) Pharmacokinetics and pharmacodynamics of three dosages of oestriol after continuous vaginal ring administration for 21 days in healthy, postmenopausal women. British Journal of Clinical Pharmacology 85:3, pages 551-562.
Crossref
Crossref
Vincenzina Bruni & Francesca Pampaloni. 2019. Menstrual Cycle Related Disorders. Menstrual Cycle Related Disorders
111
142
.
Meghan S Vermillion, Rebecca L Ursin, Sarah E Attreed & Sabra L Klein. (2018) Estriol Reduces Pulmonary Immune Cell Recruitment and Inflammation to Protect Female Mice From Severe Influenza. Endocrinology 159:9, pages 3306-3320.
Crossref
Crossref
María-Dolores Veiga, Roberto Ruiz-Caro, Araceli Martín-Illana, Fernando Notario-Pérez & Raúl Cazorla-Luna. 2018. Polymer Gels. Polymer Gels
197
246
.
Anne Lethaby, Reuben Olugbenga Ayeleke & Helen Roberts. (2016) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2016:11.
Crossref
Crossref